Barclays raised the firm’s price target on Summit Therapeutics (SMMT) to $16 from $13 and keeps an Underweight rating on the shares. The firm updated the company’s model to include colorectal cancer but says “key questions remain.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit Therapeutics Advances Ivonescimab Development Amid Financial Growth
- Summit Therapeutics Launches New Phase III Study
- Summit Therapeutics price target lowered to $32 from $33 at Clear Street
- Morning Movers: Cleveland-Cliffs surges following earnings report
- Options Volatility and Implied Earnings Moves Today, October 20, 2025